EUVIMEDEUVIMED entdecken
Crossref

CytoSorb® therapy: a new approach to treat critically ill patients with COVID-19 – a retrospective study

K. Patil, M. Priyadarsini

International Journal of Medical Device and Adjuvant Treatments · 2023-06 · 6

DOI: 10.32113/ijmdat_20236_401 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Medical Device and Adjuvant Treatments, 2023-06. Verfasst von K. Patil und 1 weiteren Autor:innen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

The Coronavirus 2019 (COVID-19) pandemic has resulted in significant mortality and morbidity. Patients with severe COVID-19 infection experience cytokine storm that makes the treatment approach more challenging. The aim of the present study was to evaluate the effects of CytoSorb® therapy in COVID-19 patients admitted in ICU. Patients and Methods: This was a single-center, retrospective study conducted at Sunshine Hospital, Hyderabad, India from January 2020 to November 2020. Patients diagnosed with COVID-19 along with signs of sepsis and with a minimum of one organ dysfunction were enrolled in the study. All the patients were treated with CytoSorb® therapy. Clinical and laboratory parameters such as procalcitonin (PCT), serum lactate, interleukin-6 (IL-6), mean arterial pressure (MAP), C-Reactive Protein and the patients’ length of stay in intensive care were measured.

Results

A total of 20 patients were enrolled in this study; of these 13 patients (65%) survived. One patient left against medical advice and was thus excluded from the analysis. Post CytoSorb® therapy, a reduction in the levels of PCT, total leucocyte count (TLC), and platelet count in the survivor group was reported. The dosage of norepinephrine decreased by 46% in the survivor group but decreased by 0.8% in the non-survivor group (p= 0.0424 for survivor vs. non survivors). The average number of days spent by all patients in ICU was 9±5.25.

Conclusions

The use of CytoSorb® therapy for patients with COVID-19 is a safe and effective treatment option when initiated in a timely manner.

Schlagwörter

cytokinescovid-19sepsishemoadsorptionacute respiratory distress syndromecoronaviruscytosorb®

Zitieren

APA

Patil, K., & Priyadarsini, M. (2023). CytoSorb® therapy: a new approach to treat critically ill patients with COVID-19 – a retrospective study. International Journal of Medical Device and Adjuvant Treatments, 6. https://doi.org/10.32113/ijmdat_20236_401

Vancouver

Patil K, Priyadarsini M. CytoSorb® therapy: a new approach to treat critically ill patients with COVID-19 – a retrospective study. International Journal of Medical Device and Adjuvant Treatments. 2023;6. doi:10.32113/ijmdat_20236_401

BibTeX
@article{Patil2023,
  author = {Patil, K. and Priyadarsini, M.},
  title = {CytoSorb® therapy: a new approach to treat critically ill patients with COVID-19 – a retrospective study},
  journal = {International Journal of Medical Device and Adjuvant Treatments},
  year = {2023},
  volume = {6},
  doi = {10.32113/ijmdat_20236_401}
}
Kostenlos starten →